Expedia Group Inc vs Novartis AG — how do they compare? Expedia Group Inc trades at $264.52 (market cap $32.06B), while Novartis AG trades at $152.36 (market cap $287.66B). The key difference: Novartis AG is far larger — about 9× Expedia Group Inc's market cap, and Novartis AG pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| EXPE | NVS | |
|---|---|---|
Market Cap | $32.06B | $287.66B |
Sector | Consumer Cyclical | Health |
52-Week High | $301.31 | $168.62 |
52-Week Low | $178.06 | $113.50 |
Enterprise Value | $30.97B | $327.68B |
Dividend Yield | 0.66% | 3.14% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.
While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →